Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-12-21
2009-12-08
Rao, Manjunath N (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S325000, C435S375000, C435S069100, C530S350000, C530S300000, C530S351000, C530S399000, C536S023400, C536S023500
Reexamination Certificate
active
07629135
ABSTRACT:
The present disclosure relates to compositions and methods of modulating inflammatory and immune responses through binding of SAA to TLR2 in a subject (e.g., human, non-human primate, rodent, etc.), and compositions and methods for screening TLR2 agonists and antagonists. In the studies described herein, a potential role of SAA in neutrophilia was investigated and the results demonstrated that SAA is a potent inducer for macrophage secretion of G-CSF, which leads to neutrophilia in mice. Using G-CSF−/−and TLR2−/−mice, it was found that the SAA-induced neutrophilia is dependent on TLR2-mediated production of G-CSF. Based on direct binding assay and gain-of-function studies in TLR2-transfected cells, SAA was identified as a novel ligand for TLR2 and a link between increased SAA concentration and TLR2-mediated inflammatory responses such as neutrophilia was established. Additional embodiments are disclosed.
REFERENCES:
patent: 2005/0004144 (2005-01-01), Carson et al.
patent: 2005/0113345 (2005-05-01), Chow et al.
patent: 2005/0119273 (2005-06-01), Lipford et al.
patent: 2005/0163764 (2005-07-01), Medzhitov et al.
patent: 2005/0208470 (2005-09-01), Latz et al.
patent: 2006/0147427 (2006-07-01), Penninger et al.
patent: 2006/0153844 (2006-07-01), Kundig et al.
patent: 2006/0179499 (2006-08-01), Tirabassi et al.
patent: 2006/0229233 (2006-10-01), Frenkel et al.
patent: WO-2004/093778 (2004-11-01), None
patent: WO-2005/102040 (2005-11-01), None
patent: WO-2006/071583 (2006-07-01), None
patent: WO-2007/053428 (2007-05-01), None
patent: WO-2007/053455 (2007-05-01), None
Papadimitraki et al 2007. Jnl of Autoimmunity. 29:310-318.
Uhlar et al 1999. Eur J. Biochem. 265:501-523.
Hamilton. 2008. Nature Reviews, Immunology. 8:533-544.
Migita et al (2004. FEBS Letters 569:235-239.
Hiratsuka et al 2008. Nature Cell Biology 10:1349-1355.
He et al., Serum amyloid a is an endogenous ligand that differentially induces IL-12 and IL-23.J. Immunol. 177: 4072-4079 (2006).
LeBouder et al., Soluble forms of toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk.J. Immunol. 171: 6680-9 (2003).
Meng et al., Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes.J. Clin. Invest. 113:1473-81 (2004).
Rutz et al., Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner.Eur. J. Immunol. 34: 2541-50 (2004).
Wyllie et al., Evidence for an accessory protein function for Toll-like receptor 1 in antibacterial responses.J. Immunol. 165: 7125-32 (2000).
Yang et al., Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signaling,Nature. 395: 284-8 (1998).
Cheng Ni
He Rong L.
Ye Richard D.
Marshall & Gerstein & Borun LLP
Rao Manjunath N
Shafer Shulamith H
The Board of Trustees of the University of Illinois
LandOfFree
Toll-like receptor agonists and antagonists and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Toll-like receptor agonists and antagonists and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Toll-like receptor agonists and antagonists and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4148754